drugset / Trial / NCT06194032

A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants

NCT06194032

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedCrossoverTriple-blindTreatment

Summary

This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF) compared to placebo using a concentration-QTcF analysis, and with moxifloxacin as positive control, in healthy participants.

Timeline

Start
2024-02-29
Primary completion
2024-05-13
Completion
2024-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Baxdrostat Small molecule Oral
Subject Moxifloxacin Small molecule

Indications

No indication recorded.